NCM · Biotechnology

FBRX (FBRX) Stock

$76.99 +0.00% NCM: FBRX Healthcare

Valuation

MetricValue
Price$76.99
Market Cap$1.58B
P/E Ratio-4.26
P/B Ratio4.57
P/S Ratio0.00
EPS (TTM)$-4.71
52-Week High$77.00
52-Week Low$9.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-113.11%
ROA-83.13%
ROCE-116.39%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio3.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-21.0M$-14.0M$-32.0M$-37.0M$-71.0M
Net Profit$-22.0M$-14.0M$-31.0M$-35.0M$-69.0M
EPS$-38.85$-19.96$-24.92$-12.17$-4.71
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$43.0M$42.0M$39.0M$62.0M$83.0M
Total Liabilities$2.0M$3.0M$4.0M$9.0M$22.0M
Cash$42.0M$41.0M$12.0M$22.0M$77.0M
Borrowings$0$0$0$0$0

Latest News

TRAX Stock Hits All-Time High — What's Driving The Super Rally? Stocktwits · Jul 10, 2026 FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data Zacks · Jul 10, 2026 Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement MarketBeat · Jul 10, 2026 Top Midday Gainers MT Newswires · Jul 9, 2026 Forte Biosciences shares surge after positive phase 1b vitiligo results Proactive · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-17.0M$-8.0M$-29.0M$-31.0M$-51.0M
Investing Cash Flow$0$0$0$-36.0M$36.0M
Financing Cash Flow$0$0$0$-1.0M$-7.0M
Net Cash Flow$-17.0M$-1.0M$-4.0M$-15.0M$55.0M
Free Cash Flow$-17.0M$-8.0M$-29.0M$-31.0M$-51.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-20.93%
Quick Ratio2.75
Interest Coverage—
Return 1Y461.09%
Return 3Y136.44%
Return 5Y-94.39%

About FBRX

FBRX is led by CEO Paul A. Wagner, employs 14 people, headquartered in US, publicly traded since 2017.

FBRX stock trades at $76.99 with a market capitalization of $1.58B. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.26, reflecting a net loss over the last twelve months, price-to-book of 4.57, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $9.10 and $77.00, and currently trades at or near its 52-week high.

On profitability, FBRX generates a return on equity (ROE) of -113.11% (negative, reflecting a net loss), return on capital employed of -116.39%.

FBRX by the numbers, 2016–2025

Between 2016 and 2025 FBRX reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-69.0M.

On a trailing twelve-month basis to Mar '26, revenue is $0 and net profit $-76.0M.

Borrowings fell from $21.0M to $0, cash from operations was $-51.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -71.5% over five years, and was -113.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

FBRX (FBRX) — frequently asked questions

What is FBRX (FBRX) stock price today?

FBRX (FBRX) is currently trading at $76.99, up 0% today.

What is FBRX P/E ratio?

FBRX's P/E ratio is -4.26. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is FBRX return on equity (ROE)?

FBRX's return on equity (ROE) is -113.11%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is FBRX's market cap?

FBRX has a market capitalization of $1.58B.

Does FBRX pay a dividend?

FBRX is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does FBRX carry?

FBRX has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is FBRX's profit margin?

FBRX reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is FBRX in?

FBRX is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is FBRX listed on?

FBRX trades on NCM under the ticker FBRX.

What is FBRX's 52-week range?

Over the last year FBRX has traded between $9.10 and $77.00.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens FBRX currently matches

On the figures above, FBRX passes the filters for 7 of our ready-made screens, among them Low Debt Stocks, Small Cap Stocks, Debt Free Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Low Debt StocksSmall Cap StocksDebt Free Stocks Under $100Debt Free StocksStocks Under $100Debt to Equity Below 1 StocksHigh Current Ratio Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.